Health Care

AbbVie & Genmab’s tucatinib‑GA101 combo shows 70% response in relapsed DLBCL, promising accelerated approval and new oncology revenue.

German lab‑tech maker Sartorius AG surged 2‑3% on Oct 6 as EU biotech and diagnostics rally, buoyed by a U.S. biotech takeover talk and a bullish market backdrop.

Explore Bayer AG’s $2.2 billion global capacity boost and breakthrough Parkinson’s drug pipeline—insights on supply resilience, cost‑efficiency, and patient access.

German DAX gains ~1% as lower oil prices and U.S. Treasury yields lift corporate costs, boosting pharma and tech while hurting defence and telecoms.

UnitedHealth’s Q3 earnings preview: investors weigh PBM growth, cost‑control claims and a Texas probe, seeking insights on future profitability and regulatory risk.

Pfizer’s latest earnings lift shares modestly, driven by strong oncology sales, a Japanese partnership, and a new acquisition that boosts global growth and shareholder returns.

Johnson & Johnson’s Q3 earnings reveal a 7.3% revenue jump driven by consumer health and medical devices, plus a steady 20.1% margin, highlighting its growth strategy and pipeline strengths.

IncYTE Corp’s latest Form 4 shows a routine share purchase by officer Heeson Lee—no ownership shift, just standard RSU compliance and market stability.

Gilead extends its partnership with Nurix, advancing a protein‑degradation oncology platform that shows early promise, shares costs, and may boost future revenues and patient outcomes.

Discover how West Pharmaceutical’s SelfDose® platform will reshape injectable drug delivery at CPHI 2026, boosting patient adherence, reducing costs, and unlocking new market growth.